{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:02:14Z","timestamp":1794200534974,"version":"4.8.0"},"reference-count":18,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2022,9,21]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Lipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global ASCVD population and identify racial, ethnic, regional and gender differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre cross-sectional epidemiological study to estimate the prevalence of elevated Lp(a) in patients with a history of myocardial infarction, ischaemic stroke or peripheral artery disease conducted at 949 sites in 48 countries in North America, Europe, Asia, South America, South Africa and Australia between April 2019 and July 2021. Low-density lipoprotein cholesterol (LDL-C) and Lp(a) levels were measured either as mass (mg\/dL) or molar concentration (nmol\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 48 135 enrolled patients, 13.9% had prior measurements of Lp(a). Mean age was 62.6 (SD 10.1) years and 25.9% were female. Median Lp(a) was 18.0 mg\/dL (IQR 7.9\u201357.1) or 42.0 nmol\/L (IQR 15.0\u2013155.4). Median LDL-C was 77 mg\/dL (IQR 58.4\u2013101.0). Lp(a) in women was higher, 22.8 (IQR 9.0\u201373.0) mg\/dL, than in men, 17.0 (IQR 7.1\u201352.2) mg\/dL, p&lt;0.001. Black patients had Lp(a) levels approximately threefold higher than white, Hispanic or Asian patients. Younger patients also had higher levels. 27.9% of patients had Lp(a) levels &gt;50 mg\/dL, 20.7% had levels &gt;70 mg\/dL, 12.9% were &gt;90 mg\/dL and 26.0% of patients exceeded 150 nmol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Globally, Lp(a) is measured in a small minority of patients with ASCVD and is highest in black, younger and female patients. More than 25% of patients had levels exceeding the established threshold for increased cardiovascular risk, approximately 50 mg\/dL or 125 nmol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2022-002060","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T11:14:40Z","timestamp":1666005280000},"page":"e002060","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":141,"title":["Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E","family":"Nissen","sequence":"first","affiliation":[{"name":"Cleveland Clinic Cardiovascular Coordinating Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cardiovascular Coordinating Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cardiovascular Coordinating Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Victorian Heart Institute, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Leitersdorf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hadassah Medical Center, Jerusalem, Israel"},{"name":"Israel and Faculty of Medicine, the Hebrew University, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 University Medicine Berlin, German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin Institute of Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Blaha","sequence":"additional","affiliation":[{"name":"Johns Hopkins, Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cardiovascular Coordinating Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Center of Medical Innovation and Translational Research School of Medicine, Osaka University, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Liu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Manning","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plamen","family":"Kozlovski","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lesogor","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Thuren","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibasaki","sequence":"additional","affiliation":[{"name":"Saitama Sekishinkai Hospital, Sayama-city, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Matei","sequence":"additional","affiliation":[{"name":"Clinica Matcord, Buz\u0103u, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio Serra","family":"Silveira","sequence":"additional","affiliation":[{"name":"Research Center Cl\u00ednica do Cora\u00e7\u00e3o, Aracaju-SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meunch","sequence":"additional","affiliation":[{"name":"SEC Clinical Research, Andalusia, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysha","family":"Bada","sequence":"additional","affiliation":[{"name":"Chris Hani Baragwanath Hospital, Soweto, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Vijan","sequence":"additional","affiliation":[{"name":"Vijan Cardiac & Critical Care Centre, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Eske","family":"Bruun","sequence":"additional","affiliation":[{"name":"Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital - Herlev Gentofte, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2025081711101915000_9.2.e002060.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063"},{"key":"2025081711101915000_9.2.e002060.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"2025081711101915000_9.2.e002060.3","article-title":"The task force for the management of dyslipidaemias of the European Society of cardiology (ESC) and European atherosclerosis Society (EAS). 2019 ESC\/EAS guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","year":"2020","journal-title":"European Heart Journal"},{"key":"2025081711101915000_9.2.e002060.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239"},{"key":"2025081711101915000_9.2.e002060.5","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2025081711101915000_9.2.e002060.6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"2025081711101915000_9.2.e002060.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.045120"},{"key":"2025081711101915000_9.2.e002060.8","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-316586"},{"key":"2025081711101915000_9.2.e002060.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.715698"},{"key":"2025081711101915000_9.2.e002060.10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025081711101915000_9.2.e002060.11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025081711101915000_9.2.e002060.12","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.023689"},{"key":"2025081711101915000_9.2.e002060.13","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R061648"},{"key":"2025081711101915000_9.2.e002060.14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacl.2018.02.014","article-title":"Relationship between \"LDL-C\", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide","volume":"12","author":"Viney","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2025081711101915000_9.2.e002060.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100053"},{"key":"2025081711101915000_9.2.e002060.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61252-1"},{"key":"2025081711101915000_9.2.e002060.17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2025081711101915000_9.2.e002060.18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"}],"updated-by":[{"DOI":"10.1136\/openhrt-2022-002060corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000}}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2022-002060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T18:10:22Z","timestamp":1755454222000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2022-002060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/openhrt-2022-002060"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2022-002060","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}